Cagrilintide and Eloralintide are each a copy of amylin.
Amylin is the fullness hormone your pancreas releases alongside insulin.
| Comparison | Cagrilintide AM833 · EZP-CG | Eloralintide LY3841136 |
|---|---|---|
| How it works | How it works Cagrilintide copies amylin rather than GLP-1. Amylin is a separate fullness hormone your pancreas releases alongside insulin, which is why it can be combined with a GLP-1 drug instead of competing with one. | How it works Eloralintide is an amylin receptor agonist designed with tolerability as the main goal. |
| What it is | A weekly fullness-hormone shot, often paired with semaglutide for bigger loss. | An experimental weekly fullness-hormone shot for weight loss. |
| Status | In trialsInvestigational | In trialsInvestigational |
| Typical dose | 0.3–4.5 mg per dose | 1–9 mg per week |
| How often | Weekly | Weekly |
| Stays active | About 8 days | 14 to 16 days |
| Dose comes from | Clinical trial protocol | Clinical trial protocol |
| Cycled? | Not cycled in the trials Clinical trial protocol | Not cycled in the trials Clinical trial protocol |
| What it does | ||
| Drug class | Amylin analog | Amylin agonist |
| Used for | People use it to feel full and eat less by copying a natural fullness hormone. It is often paired with semaglutide for bigger weight loss. | An experimental weekly shot that copies a natural fullness hormone for weight loss, positioned as easy to tolerate. |
| Receptors hit | amylin | amylin |
| Numbers | ||
| Full dose line | 0.3 up to 4.5 mg per dose (start low, increase slowly) | 1 up to 9 mg per week (trial doses) |
| Why that cycle | Given continuously for the whole study period: 26 weeks on its own, 68 weeks as part of REDEFINE 1. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Given continuously for the whole study period: 48 weeks in phase 2, 75 to 80 weeks in phase 3. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | 37 residues |
| Common vial | 10 mg | 10 mg |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | No formal contraindications established, since it is still investigational Pregnancy Caution alongside other blood-sugar-lowering medicines | No formal contraindications established Pregnancy |
What people actually report
Cagrilintide
- Nausea and other stomach side effects are common.
- It is not approved on its own and is still increased slowly from low doses in trials.
- Severe stomach pain that spreads to your back
- Vomiting badly enough that you cannot keep fluids down
Eloralintide
- Stomach side effects.
- Trial-only.
- Vomiting badly enough that you cannot keep fluids down
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.